The FDA has OK'd the use of Amgen's ($AMGN) Vectibix as a first-line treatment for wild-type KRAS metastatic colorectal cancer. The agency approved the frontline use of the drug in combination with Folfox chemotherapy. Vectibix was initially approved 8 years ago for solo use among patients with EGFR-expressing cases of colorectal cancer as a second-line therapy--after their disease had progressed following various chemo treatments. In a pair of late-stage trials, Amgen demonstrated that combining Vectibix with a Folfox regimen could amp up overall survival rates in patients with wild-type KRAS tumors, pushing the average OS rate from 19.4 months from the chemo-only group to 23.8 months in the combo arm. Story